Adicet Completes Last Patient Visit for SLE Study; Plans to Report Data This Month
Adicet Bio reported the completion of a key SLE study for prula-cel, with topline data expected in September 2026. The company also announced FDA clearance for its ADI-212 mCRPC program.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day